| Serial Number | 88443079 |
| Word Mark | THERADIGM |
| Filing Date | Thursday, May 23, 2019 |
| Status | 606 - ABANDONED - NO STATEMENT OF USE FILED |
| Status Date | Monday, January 2, 2023 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, October 1, 2019 |
| Goods and Services | Biomanufacturing for others, namely, manufacturing of biologics, cells, scaffolds and matrices, and related biological materials using biological organisms in the manufacturing process |
| Goods and Services | Biologics, namely, cells and cell lines for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Stem cells and progenitor cells for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Bone Marrow Stromal Cells (BMSCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Adipose tissue stromal cells (ASCs) for use as therapeutics to repair, replace or preserve cells and tissues, or to mobilize the immune system, including against pathogens or cancers, or to modulate the immune system, including against auto-immune disease or inflammatory conditions; Growth factors for use as medicinal products, namely, cell growth media for growing cells for medical or clinical use; Proteins for use as medicinal products, namely, protein arrays for medical diagnosis purposes; Peptides for use as medicinal products, namely, synthetic peptides for the treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, heart and vasculature disorders, and cancer; Clinical medical reagents, namely, small molecules for use as medicinal products; Clinical medical reagents, namely, telomerase activators (agonists) and inhibitors (antagonists) for use as medicinal products; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of Central Nervous System (CNS) disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Pharmaceutical preparations, namely, cell-based therapeutics for the treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, peripheral neural disorders, autism, Multiple Sclerosis (MS), and MS-like diseases with cognitive dysfunction, mobility dysfunction, and neurological disorders; Pharmaceutical preparations for the treatment of the Central Nervous System (CNS), namely, stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's disease, Huntington's disease, Multiple Sclerosis (MS), and cognitive dysfunction, mobility dysfunction, and neurological disorders, peripheral neural disorders, and autism |
| Goods and Services | Biologics, namely, cells and cell lines for scientific and research use in the development, testing and manufacture of therapeutics; Biologics, namely, cells and cell lines for scientific and research use in the production of biologic substances, including growth factors and proteins; Biologics, namely, cells and cell lines for scientific and research use for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, stem cells and progenitor cells for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, Bone Marrow Stromal Cells (BMSCs) for the testing of chemical substances; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the development, testing and manufacture of therapeutics; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for use in the production of biologic substances, including growth factors and proteins; Cells and cell lines for scientific and research use, namely, adipose tissue stromal cells (ASCs) for the testing of chemical substances |
| Goods and Services | Medical testing for diagnostic or treatment purposes; Medical treatment of neuro-degenerative disorders, metabolic disorders, inflammatory and auto-immune disorders, orthopedic disorders, and heart and vasculature disorders; Medical treatment of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical treatment of Central Nervous System (CNS) disorders; Medical treatment of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical treatment, namely, cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells; Medical and pharmaceutical consultation in the field of Central Nervous System (CNS) disorders; Medical and pharmaceutical consultation in the field of stroke, spinal cord injury, brain injury, brain tumors, Amyotrophic Lateral Sclerosis (ALS) (Lou Gehrig's Disease), Parkinson's Disease, Huntington's Disease, Multiple Sclerosis (MS), and MS-like diseases, peripheral neural disorders, and autism; Medical and pharmaceutical consultation in the field of cell-based therapies for the treatment of neurological and Central Nervous System (CNS) injuries and disorders, demyelinating disorders, auto-immune disorders, peripheral neural disorders, and autism |
| Goods and Services | Pharmaceutical research and development services; Biological research and development services; Medical research and development services in the field of regenerative medicine and immunotherapies; Medical and pharmaceutical research in the field of stem and progenitor cells and bone marrow stromal cells and adipose tissue stromal cells |
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 7, 2019 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 7, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 040 - Treatment of materials. |
| US Class Codes | 100, 103, 106 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 7, 2019 |
| Primary Code | 040 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 7, 2019 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, June 7, 2019 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Vesta Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | Hanover, MD 21076 |
| Party Name | Vesta Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | Hanover, MD 21076 |
| Event Date | Event Description |
| Tuesday, January 3, 2023 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Monday, January 2, 2023 | ABANDONMENT - NO USE STATEMENT FILED |
| Tuesday, May 24, 2022 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, May 23, 2022 | SOU EXTENSION 5 GRANTED |
| Wednesday, May 18, 2022 | SOU EXTENSION 5 FILED |
| Monday, May 23, 2022 | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Wednesday, May 18, 2022 | SOU TEAS EXTENSION RECEIVED |
| Friday, January 28, 2022 | ASSIGNED TO EXAMINER |
| Thursday, October 28, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, October 26, 2021 | SOU EXTENSION 4 GRANTED |
| Tuesday, October 26, 2021 | SOU EXTENSION 4 FILED |
| Tuesday, October 26, 2021 | SOU TEAS EXTENSION RECEIVED |
| Thursday, April 29, 2021 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Tuesday, April 27, 2021 | SOU EXTENSION 3 GRANTED |
| Tuesday, April 27, 2021 | SOU EXTENSION 3 FILED |
| Tuesday, April 27, 2021 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, November 18, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Monday, November 16, 2020 | SOU EXTENSION 2 GRANTED |
| Monday, November 16, 2020 | SOU EXTENSION 2 FILED |
| Monday, November 16, 2020 | SOU TEAS EXTENSION RECEIVED |
| Saturday, May 9, 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Thursday, May 7, 2020 | SOU EXTENSION 1 GRANTED |
| Thursday, May 7, 2020 | SOU EXTENSION 1 FILED |
| Thursday, May 7, 2020 | SOU TEAS EXTENSION RECEIVED |
| Tuesday, November 26, 2019 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Tuesday, October 1, 2019 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, October 1, 2019 | PUBLISHED FOR OPPOSITION |
| Wednesday, September 11, 2019 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Thursday, August 29, 2019 | ASSIGNED TO LIE |
| Wednesday, August 21, 2019 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Monday, August 19, 2019 | EXAMINER'S AMENDMENT ENTERED |
| Monday, August 19, 2019 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, August 19, 2019 | EXAMINERS AMENDMENT E-MAILED |
| Monday, August 19, 2019 | EXAMINERS AMENDMENT -WRITTEN |
| Tuesday, August 13, 2019 | ASSIGNED TO EXAMINER |
| Friday, June 7, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, May 27, 2019 | NEW APPLICATION ENTERED |